Breast cancer test gave Atossa a revenue boost in Q2

08/16/2013 | GenomeWeb Daily News (free registration)

Atossa Genetics posted $326,078 in revenue during the second quarter, up from $223,097 in the same period last year. The increase was fueled by sales of the company's ForeCYTE Breast Health Test, which stratifies patients' breast cancer risk based on mammary aspirate samples.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA